A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between
imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly.
Primary endpoint: To compare at 12 months between the treatment arms the rate of Major
Molecular Response (=99,9% tumour reduction) at 12 months
Phase:
Phase 2
Details
Lead Sponsor:
Uppsala University
Collaborators:
Karolinska University Hospital Uppsala University Hospital